Efficacy And Safety Of Qva149 Versus Glycopyrronium And Tiotropium In A Subgroup Of Patients With Severe COPD: The Spark Study

被引：0
|
作者：
Wedzicha, J. [1 ]
D'Urzo, A. D. [2 ]
Decramer, M. [3 ]
Ficker, J. H. [4 ]
Sandstrom, T. [5 ]
Taylor, A. Fowler [6 ]
D'Andrea, P. [6 ]
Mezzi, K. [7 ]
Chen, H. [6 ]
Banerji, D. [6 ]
Fogel, R. [6 ]
机构：
[1] UCL, London, England
[2] Univ Toronto, Toronto, ON, Canada
[3] Katholieke Univ Leuven, Univ Hosp, Leuven, Belgium
[4] Klinikum Nuernberg, Nurnberg, Germany
[5] Umea Univ, Umea, Sweden
[6] Novartis Pharmaceut, E Hanover, NJ USA
[7] Novartis Pharma AG, Basel, Switzerland
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2014年 / 189卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A5986
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Efficacy And Safety Of Qva149 Versus Glycopyrronium And Tiotropium In Severe To Very Severe COPD: The Spark Study
    Wedzicha, J. A.
    Decramer, M.
    Ficker, J.
    Niewoehner, D. E.
    Sandstrom, T.
    Taylor, A. Fowler
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [2] Safety And Tolerability Of Qva149, Glycopyrronium And Tiotropium In Patients With Severe To Very Severe COPD: The Spark Study
    Decramer, M.
    Wedzicha, J. A.
    Sandstrom, T.
    Niewoehner, D.
    Taylor, A. Fowler
    D'Andrea, P.
    Arrasate, C.
    Berhane, I.
    Chen, H.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [3] QVA149 versus glycopyrronium for COPD
    Van Meerhaeghe, Alain
    Vanhaeverbeek, Michel
    LANCET RESPIRATORY MEDICINE, 2013, 1 (05): : E22 - E23
  • [4] QVA149 versus glycopyrronium for COPD Reply
    Wedzicha, Jadwiga A.
    Decramer, Marc
    Ficker, Joachim H.
    Niewoehner, Dennis E.
    Sandstrom, Thomas
    Taylor, Angel Fowler
    D'Andrea, Peter
    Arrasate, Christie
    Chen, Hungta
    Banerji, Donald
    LANCET RESPIRATORY MEDICINE, 2013, 1 (05): : E23 - E23
  • [5] Impact of tiotropium on exacerbations versus glycopyrronium and QVA149
    Metzdorf, Norbert
    Hallmann, Christoph
    Disse, Bernd
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2015, 9 (06) : 675 - 676
  • [6] impact of tiotropium on exacerbations versus glycopyrronium and QVA149 Response
    Riario-Sforza, Gian Galeazzo
    Ridolo, Erminia
    Riario-Sforza, Edoardo
    Incorvaia, Cristoforo
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2015, 9 (06) : 677 - 677
  • [7] Qva149 Provides Greater Improvement In Patient Reported Symptom Scores Compared To Glycopyrronium And Tiotropium In Patients With Severe To Very Severe COPD: The Spark Study
    Wedzicha, J.
    Decramer, M.
    Ficker, J.
    Sandstrom, T.
    Taylor, A.
    D'Andrea, P.
    Fogel, R.
    Mezzi, K.
    Chen, H.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [8] Once-Daily QVA149 Reduces Exacerbations and Improves Health Status in Comparison With Glycopyrronium and Tiotropium in Patients With Severe-to-Very Severe COPD: The SPARK Study
    Wedzicha, Jadwiga
    Ficker, Joachim
    FowlerTaylor, Angel
    D'Andrea, Peter
    Arrasate, Christie
    Chen, Hungta
    Banerji, Donald
    CHEST, 2014, 145 (03)
  • [9] Once-daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe-to-very severe COPD: The SPARK study
    Decramer, Marc
    Wedzicha, Jadwiga A.
    Ficker, Joachim H.
    FowlerTaylor, Angel
    D'Andrea, Peter
    Arrasate, Christie
    Chen, Hungta
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [10] QVA149 Improves Lung Function and Reduces Exacerbations Compared With Tiotropium in Patients With Severe-to-Very Severe COPD: The SPARK Study
    Ficker, Joachim
    Wedzicha, Jadwiga
    FowlerTaylor, Angel
    D'Andrea, Peter
    Arrasate, Christie
    Chen, Hungta
    Banerji, Donald
    CHEST, 2014, 145 (03)
12345